Brokerages expect that Oragenics, Inc. (NASDAQ:OGEN) will report earnings of ($0.09) per share for the current quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Oragenics’ earnings, with estimates ranging from ($0.11) to ($0.06). Oragenics posted earnings of ($0.35) per share in the same quarter last year, which would indicate a positive year-over-year growth rate of 74.3%. The firm is scheduled to issue its next quarterly earnings results on Tuesday, November 12th.
On average, analysts expect that Oragenics will report full year earnings of ($0.38) per share for the current year, with EPS estimates ranging from ($0.43) to ($0.33). For the next year, analysts anticipate that the company will post earnings of ($0.30) per share, with EPS estimates ranging from ($0.36) to ($0.23). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research firms that follow Oragenics.
Oragenics (NASDAQ:OGEN) last issued its quarterly earnings data on Wednesday, August 14th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.07) by ($0.03).
Oragenics, Inc develops novel antibiotics against infectious diseases and treatments for oral mucositis. It is developing OG716, an antibiotic product candidate, which is in nonclinical testing for healthcare-associated infections, as well as other homolog antibiotic product candidates. The company is also developing AG013, which is in Phase II clinical trial for the treatment of oral mucositis in cancer patients.
Featured Story: Investing in Growth Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Oragenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oragenics and related companies with MarketBeat.com's FREE daily email newsletter.